BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Horinouchi H, Atagi S, Oizumi S, Ohashi K, Kato T, Kozuki T, Seike M, Sone T, Sobue T, Tokito T, Harada H, Maeda T, Mio T, Shirosaka I, Hattori K, Shin E, Murakami H. Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study. Cancer Med 2020;9:6597-608. [PMID: 32730697 DOI: 10.1002/cam4.3306] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study. J Thorac Oncol 2023;18:181-93. [PMID: 36307040 DOI: 10.1016/j.jtho.2022.10.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Bi N, Xu K, Ge H, Chen M, E M, Zhang L, Cao J, Zhang X, Ding X, Xia B, Zhao L, Han L, Li J, Hu C, Wang L. Real-world treatment patterns and clinical outcomes in EGFR-mutant locally advanced lung adenocarcinoma: a multi-center cohort study. Journal of the National Cancer Center 2022. [DOI: 10.1016/j.jncc.2022.11.003] [Reference Citation Analysis]
3 Sakagami M, Inokuchi H, Mukumoto N, Itoyama H, Hamaura N, Yamagishi M, Mukumoto N, Matsuda S, Shibuya K. Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer.. [DOI: 10.21203/rs.3.rs-1974420/v1] [Reference Citation Analysis]
4 Sugimoto T, Fujimoto D, Sato Y, Tamiya M, Yokoi T, Taniguchi Y, Hino A, Hata A, Uchida J, Fukuda Y, Hara S, Kanazu M, Matsumoto H, Kokubo M, Yamamoto N. Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis. Lung Cancer 2022;171:3-8. [PMID: 35863254 DOI: 10.1016/j.lungcan.2022.07.005] [Reference Citation Analysis]
5 Li J, Xu J, Yang M, Zhou Q. Therapeutic revolution for inoperable stage III non-small cell lung cancer in the immune era. Cancer Biol Med 2022:j. [PMID: 35676755 DOI: 10.20892/j.issn.2095-3941.2022.0254] [Reference Citation Analysis]
6 Yamamoto T, Tsukita Y, Katagiri Y, Matsushita H, Umezawa R, Ishikawa Y, Takahashi N, Suzuki Y, Takeda K, Miyauchi E, Saito R, Katsuta Y, Kadoya N, Jingu K. Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice. BMC Cancer 2022;22:364. [PMID: 35379201 DOI: 10.1186/s12885-022-09354-1] [Reference Citation Analysis]
7 Miyawaki E, Kenmotsu H, Shintani Y, Sekine I, Shukuya T, Takayama K, Inoue A, Okamoto I, Kiura K, Takahashi K, Yamamoto N, Kawaguchi T, Miyaoka E, Yoshino I, Date H. Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study. BMC Cancer 2022;22:342. [PMID: 35351059 DOI: 10.1186/s12885-022-09441-3] [Reference Citation Analysis]
8 Mayahara H, Uehara K, Harada A, Kitatani K, Yabuuchi T, Miyazaki S, Ishihara T, Kawaguchi H, Kubota H, Okada H, Ninomaru T, Shindo C, Hata A. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer. Radiat Oncol 2022;17:7. [PMID: 35033139 DOI: 10.1186/s13014-021-01979-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 A K, H S, W H, As F, P WP, A R. Consolidative durvalumab outcomes in stage III non-small cell lung cancer in a multi-centre study. Cancer Treat Res Commun 2021;29:100496. [PMID: 34864586 DOI: 10.1016/j.ctarc.2021.100496] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Murakami H, Horinouchi H, Harada H, Sobue T, Kato T, Atagi S, Kozuki T, Tokito T, Oizumi S, Seike M, Ohashi K, Mio T, Sone T, Jinushi M, Tsuboi M. Deciphering the clinical features of heterogeneous stage III non-small cell lung cancer in Japanese real-world clinical practice: expanded cohort of the SOLUTION study. Lung Cancer 2021. [DOI: 10.1016/j.lungcan.2021.12.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Nishimura A, Ono A, Wakuda K, Kawabata T, Yabe M, Miyawaki T, Miyawaki E, Kodama H, Nishioka N, Mamesaya N, Kobayashi H, Omori S, Kenmotsu H, Naito T, Murakami H, Harada H, Takahashi T. Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer. Invest New Drugs 2021. [PMID: 34633575 DOI: 10.1007/s10637-021-01191-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Saito G, Oya Y, Taniguchi Y, Kawachi H, Daichi F, Matsumoto H, Iwasawa S, Suzuki H, Niitsu T, Miyauchi E, Yokoi T, Yokoyama T, Uenami T, Sakata Y, Arai D, Okada A, Nagata K, Teraoka S, Kokubo M. Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON). Lung Cancer 2021;161:86-93. [PMID: 34543942 DOI: 10.1016/j.lungcan.2021.08.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
13 Zhang X, He Y, Jiang Y, Bao Y, Chen Q, Xie D, Yu H, Wang X. TMEM229A suppresses non‑small cell lung cancer progression via inactivating the ERK pathway. Oncol Rep 2021;46:176. [PMID: 34184076 DOI: 10.3892/or.2021.8127] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Tsukita Y, Yamamoto T, Mayahara H, Hata A, Takeda Y, Nakayama H, Tanaka S, Uchida J, Usui K, Toyoda T, Tamiya M, Morimoto M, Oya Y, Kodaira T, Miyauchi E, Jingu K, Sugiura H. Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: A multi-center retrospective study. Radiother Oncol 2021;160:266-72. [PMID: 34023330 DOI: 10.1016/j.radonc.2021.05.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
15 Kim HC, Ji W, Lee JC, Kim HR, Song SY, Choi CM; Korean Association for Lung Cancer., Korea Central Cancer Registry. Prognostic Factor and Clinical Outcome in Stage III Non-Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population. Cancer Res Treat 2021. [PMID: 33592139 DOI: 10.4143/crt.2020.1350] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
16 Sugimoto T, Fujimoto D, Sato Y, Tamiya M, Yokoi T, Tamiya A, Iwasawa S, Hata A, Uchida J, Fukuda Y, Hara S, Kanazu M, Hirano K, Kokubo M, Yamamoto N. Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study. Invest New Drugs 2021;39:853-9. [PMID: 33405089 DOI: 10.1007/s10637-020-01060-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Horinouchi H, Atagi S, Oizumi S, Ohashi K, Kato T, Kozuki T, Seike M, Sone T, Sobue T, Tokito T, Harada H, Maeda T, Mio T, Shirosaka I, Hattori K, Shin E, Murakami H. Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study. Cancer Med 2020;9:6597-608. [PMID: 32730697 DOI: 10.1002/cam4.3306] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]